Neotropix – A Leading Biotechnology Company Committed to Making a Difference in the Lives of Cancer Patients Through Innovative Lung Cancer Treatments & Much More!

Many viruses have evolved, over billions of years, to do exactly what is needed to create effective cancer therapies: kill tumor cells but not normal cells. Neotropix works to harness viruses' natural infectious and replicative properties to treat cancer and other diseases that are resistant to available therapeutic methods.

Neotropix began a Phase IA-II Clinical Trial on our first cancer drug candidate in May, 2006.

We urge you to explore Neotropix and learn about our work as a leading biotechnology company in the emerging field of virotherapy.

Neotropix is in the forefront of research and treatment in specific areas such as SCLC, NSCLC, (including large cell lung cancer), carcinoid, neuoendocrine, rhabdomyosarcoma, neuroblastoma, retinoblastoma, medulloblastoma, rhabdoid, glioblastoma and wilms.

Product Spotlight

NTX-010: NTX-010 is a novel virus that specifically attacks and kills small cell lung cancer cells and certain other neuroendocrine cancers.

Read More.

Recent News

Feb 8, 2010 - Children's Oncology Group activates Phase I study of NTX-010 in neuroendocrine pediatric cancers

Jan 15, 2010 - North Central Cancer Treatment Group activates Phase II study of NTX-010 in extensive-stage SCLC

October 8, 2008 -Scripps research team solves structure of 'beneficial' virus

Presentations

Oct, 2008 - NCI-supported Pediatric Preclinical Testing Program to present testing results with SVV-001 (NTX-010) at the 20th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland (October 21-24, 2008). 

NANETS - 2008 Neuro Endocrine Tumor Symposium

Publications

October 13,2008 - Venkataraman S, Reddy PS, Loo J, Idamakanti N, Hallenbeck PL, Reddy VS. Structure of Seneca Valley Virus-001: An Oncolytic Picornavirus Representing a New Genus. Structure. 2008. 16:1555-1561.

November, 2007: Seneca Valley Virus and the Treatment of Neuroendocrine Cancers

Press Releases

May 14, 2010 - Neotropix Announces Enrollment of Patients in NCI-Sponsored Phase II Clinical Trial for Small Cell Lung Cancer

January 14, 2009 - Frost & Sullivan Recognizes Neotropix's Approach to the Treatment of Small Cell Lung Cancer and Neuroendocrine Cancers

October 22, 2008 - Neotropix® Announces Presentation of Relevant Preclinical Results of NTX-010 in Pediatric Oncology Models

October 8, 2008 -Scripps research team solves structure of 'beneficial' virus

October 8, 2008 - Neotropix® Announces Expansion of On-going Clinical Trial
for Adult Neuroendocrine Cancers

September 23, 2008 - Neotropix Appoints Anthony Williams, M.D., as its Chief Medical Officer

May 17, 2006 - Neotropix Receives FDA Approval to Begin Clinical Trials With First Investigational Cancer Drug (PDF)